Trial Profile
Phase II Study of Carboplatin + Pemetrexed + Bevacizumab in chemo-naive patients with stage IIIB and IV non-squamous non-small cell lung cancer(NSCLC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Mar 2014 New trial record